Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.

Published in: Clinical autonomic research : official journal of the Clinical Autonomic Research Society (2019)

Clinical trials of inotersen and patisiran showed that these agents were able to halt the progression of the disease, with some patients even reducing the burden of polyneuropathy, and improving qualify of life. The information on their impact on autonomic parameters is limited, warranting further dedicated studies.

Keyphrases

clinical trial
end stage renal disease
heart rate variability
ejection fraction
newly diagnosed
heart rate
peritoneal dialysis
prognostic factors
healthcare
risk factors
social media
phase ii